Welcome to our dedicated page for KALA BIO news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on KALA BIO stock.
KALA BIO, Inc. develops a dual strategy that combines a clinical-stage biologics pipeline for rare and severe eye diseases with an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical clients. Company updates cover the MSC-S platform, the KPI-012 clinical program, Researgency.ai, and the Bionic Intelligence Research Agent for secure research, clinical, regulatory, and data-workflow applications.
News also addresses capital-structure actions and corporate-status developments, including registered equity offerings, debt settlement, Nasdaq listing matters, governance changes, and the completed 1-for-50 reverse stock split of KALA common stock.
KALA BIO (NASDAQ:KALA) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Closed a $12.5 million private placement financing
- Cash resources of $54.2 million as of June 30, 2024
- Funding expected to last into Q4 2025
- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025
The company is advancing its MSC-S platform technology, focusing on KPI-012 for PCED and exploring potential in other eye diseases. Q2 2024 financial results show a net loss of $9.6 million, or $3.16 per share, compared to $10.4 million, or $4.36 per share, in Q2 2023.
KALA BIO, a clinical-stage biopharmaceutical company, announced a private placement agreement with institutional investors to sell 1,197,314 shares of common stock at $5.85 per share and 9,393 shares of Series H Preferred Stock at $585.00 per share, raising approximately $12.5 million before expenses.
The placement, led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor, is set to close around June 28, 2024, pending customary conditions. Net proceeds will fund the clinical development of KPI-012 for persistent corneal epithelial defects and general corporate purposes.
The securities are unregistered under the Securities Act of 1933 and will only be offered via a prospectus. KALA will file a registration statement with the SEC within 30 days post-closing for resale purposes.
KALA BIO (NASDAQ:KALA) will present at the Jefferies Global Healthcare Conference on June 5, 2024, in New York, NY. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver the presentation at 12:30 p.m. ET. The company's management team is also available for one-on-one meetings on the same day. The presentation's webcast and archived recording will be accessible on the KALA website.
KALA BIO (NASDAQ: KALA) released its first quarter 2024 financial results and corporate update, emphasizing ongoing patient enrollment in the Phase 2b CHASE trial for KPI-012 targeting persistent corneal epithelial defect (PCED), with topline data expected by year-end 2024.
The company is also exploring KPI-012 for other corneal diseases like Limbal Stem Cell Deficiency (LSCD) and the preclinical KPI-014 for inherited retinal diseases.
As of March 31, 2024, KALA had cash resources of $48.5 million, expected to fund operations into 3Q 2025. First-quarter financials revealed a net loss of $11.8 million ($4.20 per share), compared to a $14.5 million loss ($6.99 per share) in the same period in 2023. G&A expenses decreased to $5.4 million, while R&D expenses increased to $6.4 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.